{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T11:57:26Z","timestamp":1769515046984,"version":"3.49.0"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Hepatitis B virus (HBV) infection poses a significant public health challenge in China. The Prevention of mother-to-child Transmission (PMTCT) strategy of combining universal hepatitis B vaccination with hepatitis B immunoglobulin (HBIG) for newborns is crucial in preventing widespread infection. In this study, we conduct health economic evaluation of three strategies: PMTCT, universal vaccination, and non-vaccination for newborns in Ningbo, China.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study developed a decision-Markov model and simulated a cohort of 100,000 newborns to assess the cost-effectiveness and cost\u2013benefit of three strategies from a healthcare system perspective. The primary outputs included total costs, life-years (LYs), quality-adjusted life-years (QALYs), incremental cost-effectiveness ratios (ICERs), benefit\u2013cost ratios (BCRs). One-way and probabilistic sensitivity analyses (PSA) were performed to verify the robustness of the model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the three strategies, the PMTCT results in the least disease burden and mortality related to hepatitis B. In comparison to a cohort of 100,000 unvaccinated infants, the PMTCT is expected to prevent 6,029 cases of acute symptomatic infections, 27,348 HBV carriers, 4,170 chronic infections, 3,597 cases of cirrhosis, 2,911 cases of hepatocellular carcinoma (HCC), and 3,930 HBV-related deaths. The ICERs for PMTCT and universal vaccination were\u202f\u2212\u202f56,371.77 yuan\/QALY and\u202f\u2212\u202f56,654.77 yuan\/QALY, respectively. The BCRs for PMTCT and universal vaccination were 19.13 and 15.95, respectively, when compared to no vaccination. The PSA revealed that all ICER scatter points are situated within the fourth quadrant, and the probability of PMTCT being cost-effective exceeds 90%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Implementing universal hepatitis B vaccination with HBIG for newborns in Ningbo demonstrated high cost-effectiveness, making the continuation of the PMTCT strategy highly recommended.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2025.1532604","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T05:25:31Z","timestamp":1744781131000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Health economic evaluation of newborn hepatitis B immunization prevention strategies in Ningbo: a Markov modeling study"],"prefix":"10.3389","volume":"13","author":[{"given":"Wei","family":"Feng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengxiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingkuan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sijia","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqi","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuaishuai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjun","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3760\/cma.j.issn.0254-6450.2020.02.007","article-title":"Trend analysis on the disease burden related to cirrhosis and other chronic liver diseases caused by hepatitis B, in China, from 1990 to 2016","volume":"41","author":"Zhang","year":"2020","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","article-title":"Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013","volume":"386","author":"Schweitzer","year":"2015","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1365-2893.2010.01266.x","article-title":"Epidemiology and prevention of hepatitis B virus infection in China","volume":"17","author":"Lu","year":"2010","journal-title":"J Viral Hepatitis"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.2147\/CLEP.S389853","article-title":"Global patterns and trends in Total burden of hepatitis B from 1990 to 2019 and predictions to 2030","volume":"14","author":"Zhang","year":"2022","journal-title":"Clin Epidemiol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S2468-1253(22)00124-8","article-title":"Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the global burden of disease study 2019","volume":"7","author":"Sheena LHHH","year":"2022","journal-title":"Lancet Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","article-title":"Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the global burden of disease study 2013","volume":"385","author":"Mohsen Naghavi","year":"2015","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.4254\/wjh.v7.i9.1233","article-title":"Chronic hepatitis B infection in pregnancy","volume":"7","author":"Lamberth","year":"2015","journal-title":"World J Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S0140-6736(09)60207-5","article-title":"Hepatitis B virus infection","volume":"373","author":"Liaw","year":"2009","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1046\/j.1440-1746.2000.0150121356.x","article-title":"Chronic hepatitis B virus infection in Asian countries","volume":"15","author":"Merican","year":"2000","journal-title":"J Gastroen Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s40273-022-01236-5","article-title":"Cost effectiveness of implementing a universal birth hepatitis B vaccination program in Ontario","volume":"41","author":"Kim","year":"2023","journal-title":"PharmacoEconomics"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.3760\/cma.j.cn112338-20210319-00226","article-title":"Cost-benefit analysis of the hepatitis B vaccination to prevent mother-to-child transmission strategies in China, 1992-2019","volume":"42","author":"Zheng","year":"2021","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.7664\/CHE201908014","article-title":"Health Economic Evaluationon Hepatitis B Vaccination Introduced into National Expanded Programme on Immunization in Ningbo","volume":"38","author":"Ye","year":"2019","journal-title":"Chinese Health Economics"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11684-020-0744-2","article-title":"Eliminating mother-to-child transmission of HBV: progress and challenges in China","volume":"14","author":"Jing","year":"2020","journal-title":"Front Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1007\/s11684-017-0598-4","article-title":"Current advances in the elimination of hepatitis B in China by 2030","volume":"11","author":"Zhang","year":"2017","journal-title":"Front Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3201\/eid2305.161477","article-title":"Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy","volume":"23","author":"Cui","year":"2017","journal-title":"China Emerg Infect Dis"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/S0928-4346(96)82012-3","article-title":"Prevalence of hepatitis B and C virus infections in the general Chinese population. Results from a nationwide cross-sectional seroepidemiologic study of hepatitis a, B, C, D, and E virus infections in China, 1992","volume":"5","author":"Xia","year":"1996","journal-title":"Int Hepatol Commun"},{"key":"ref17","volume-title":"Economic evaluation of infant hepatitis B vaccination in Ningbo City","year":"2013"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"852","DOI":"10.3760\/cma.j.issn.0254-6450.2017.07.003","article-title":"Cost-effectiveness and affordability of strategy for preventing mother-to-child transmission of hepatitis B in China","volume":"38","author":"Lin","year":"2017","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"3362","DOI":"10.1016\/j.vaccine.2014.04.045","article-title":"Risk factors associated with immunoprophylaxis failure against mother to child transmission of hepatitis B virus and hepatitis B vaccination status in Yunnan province, China","volume":"32","author":"Kang","year":"2014","journal-title":"Vaccine"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"6091","DOI":"10.1016\/j.vaccine.2014.08.078","article-title":"Effects of hepatitis B immunization on prevention of mother-to-infant transmission of hepatitis B virus and on the immune response of infants towards hepatitis B vaccine","volume":"32","author":"Zhang","year":"2014","journal-title":"Vaccine"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"100264","DOI":"10.1016\/j.eclinm.2020.100264","article-title":"Cost-effectiveness of couple-based immunization strategy to prevent mother-to-child transmission of hepatitis B virus in China: a decision-analytic Markov model","volume":"19","author":"Jing","year":"2020","journal-title":"Eclinicalmedicine"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1097\/INF.0000000000000315","article-title":"Immunoprophylaxis failure against vertical transmission of hepatitis B virus in the Chinese population: a hospital-based study and a meta-analysis","volume":"33","author":"Lin","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1093\/oxfordjournals.aje.a112370","article-title":"The e antigen and vertical transmission of hepatitis B surface antigen","volume":"105","author":"Beasley","year":"1977","journal-title":"Am J Epidemiol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1056\/NEJM197504102921503","article-title":"Vertical transmission of hepatitis B antigen in Taiwan","volume":"292","author":"Stevens","year":"1975","journal-title":"New Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1080\/21645515.2019.1688031","article-title":"Cost-effectiveness of augmenting universal hepatitis B vaccination with immunoglobulin treatment: a case study in Zhejiang Province","volume":"16","author":"Zeng","year":"2020","journal-title":"East China Hum Vacc Immunother"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21645515.2016.1141845","article-title":"Economic evaluation on infant hepatitis B vaccination combined with immunoglobulin in China, 2013","volume":"12","author":"Chen","year":"2016","journal-title":"Hum Vacc Immunother"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ijid.2018.08.024","article-title":"Cost-effectiveness analysis of hepatitis B vaccine booster in children born to HBsAg-positive mothers in rural China","volume":"78","author":"Wang","year":"2019","journal-title":"Int J Infect Dis"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.7189\/jogh.12.04043","article-title":"Costs and health impact of delayed implementation of a national hepatitis B treatment program in China","volume":"12","author":"Toy","year":"2022","journal-title":"J Glob Health"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/1477-7525-12-101","article-title":"Significant impairment of health-related quality of life in mainland Chinese patients with chronic hepatitis B: a cross-sectional survey with pair-matched healthy controls","volume":"12","author":"Zhuang","year":"2014","journal-title":"Health Qual Life Out"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1016\/j.vaccine.2009.06.035","article-title":"WHO guide for standardisation of economic evaluations of immunization programmes","volume":"28","author":"Walker","year":"2010","journal-title":"Vaccine"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"845","DOI":"10.3760\/cma.j.issn.0254-6450.2017.07.002","article-title":"Development of Markov models for economics evaluation of strategies on hepatitis B vaccination and population-based antiviral treatment in China","volume":"38","author":"Yang","year":"2017","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1016\/j.vaccine.2015.05.082","article-title":"The doses of 10 mug should replace the doses of 5 mug in newborn hepatitis B vaccination in China: a cost-effectiveness analysis","volume":"33","author":"Yin","year":"2015","journal-title":"Vaccine"},{"key":"ref33","volume-title":"Development of Markov models for hepatitis B vaccination or treatment and cost-effectiveness analysis of prophylactic Entecavir use for population based-on community in","author":"Yang","year":"2016"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"S76","DOI":"10.1016\/j.jhep.2015.01.018","article-title":"Strategies to control hepatitis B: public policy, epidemiology, vaccine and drugs","volume":"62","author":"Locarnini","year":"2015","journal-title":"J Hepatol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1001\/jama.2013.276701","article-title":"Thirty-year outcomes of the national hepatitis B immunization program in Taiwan","volume":"310","author":"Chiang","year":"2013","journal-title":"Jama-J Am Med Assoc"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1098\/rspb.1993.0102","article-title":"The influence of age on the development of the hepatitis B carrier state","volume":"253","author":"Edmunds","year":"1993","journal-title":"P Roy Soc B-Biol Sci"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1053\/j.gastro.2010.04.048","article-title":"Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study","volume":"139","author":"Liu","year":"2010","journal-title":"Gastroenterology"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1002\/hep.21612","article-title":"HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up","volume":"45","author":"Chu","year":"2007","journal-title":"Hepatology"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s40249-022-01032-5","article-title":"Impact of the national hepatitis B immunization program in China: a modeling study","volume":"11","author":"Liu","year":"2022","journal-title":"Infect Dis Poverty"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1093\/eurpub\/ckm123","article-title":"Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation","volume":"18","author":"Tilson","year":"2008","journal-title":"Eur J Pub Health"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"6770","DOI":"10.1016\/j.vaccine.2009.08.082","article-title":"Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and hepatitis B e antigen positive prevalence","volume":"27","author":"Hung","year":"2009","journal-title":"Vaccine"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ijid.2020.03.036","article-title":"Tenofovir prophylaxis for preventing mother-to-child hepatitis B virus transmission in China: a cost-effectiveness analysis","volume":"95","author":"Yin","year":"2020","journal-title":"Int J Infect Dis"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1080\/21645515.2020.1807812","article-title":"Cost-utility analysis of newborn hepatitis B immunization in Beijing","volume":"17","author":"Guo","year":"2021","journal-title":"Hum Vacc Immunother"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"e107177","DOI":"10.1371\/journal.pone.0107177","article-title":"Large variations in risk of hepatocellular carcinoma and mortality in treatment naive hepatitis B patients: systematic review with meta-analyses","volume":"9","author":"Thiele","year":"2014","journal-title":"PLoS One"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"662442","DOI":"10.3389\/fpubh.2022.662442","article-title":"Cost-benefit analysis of vaccination strategies to prevent mother-to-child transmission of the hepatitis B virus using a Markov model decision tree","volume":"10","author":"Yang","year":"2022","journal-title":"Front Public Health"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/S1473-3099(15)00158-9","article-title":"Global elimination of mother-to-child transmission of hepatitis B: revisiting the current strategy","volume":"15","author":"Thio","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"f 4503","DOI":"10.1136\/bmj.f4503","article-title":"The next step in controlling HBV in China","volume":"347","author":"Xu","year":"2013","journal-title":"Bmj-Brit Med J"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"879289","DOI":"10.3389\/fpubh.2022.879289","article-title":"Hepatitis B infection among pregnant women in China: a systematic review and Meta-analysis","volume":"10","author":"Liu","year":"2022","journal-title":"Front Public Health"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"100267","DOI":"10.1016\/j.lanwpc.2021.100267","article-title":"Hepatitis B virus infection among 90 million pregnant women in 2853 Chinese counties, 2015-2020: a national observational study","volume":"16","author":"Liu","year":"2021","journal-title":"Lancet Reg Health-W"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1002\/hep.27406","article-title":"The global burden of liver disease: the major impact of China","volume":"60","author":"Wang","year":"2014","journal-title":"Hepatology"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1002\/hep.28310","article-title":"Cost-effectiveness of active-passive prophylaxis and antiviral prophylaxis during pregnancy to prevent perinatal hepatitis B virus infection","volume":"63","author":"Fan","year":"2016","journal-title":"Hepatology"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1016\/j.vaccine.2021.04.041","article-title":"Prevention of hepatitis B mother-to-child transmission in Namibia: a cost-effectiveness analysis","volume":"39","author":"Tamandjou","year":"2021","journal-title":"Vaccine"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"e1135","DOI":"10.1542\/peds.2012-1262","article-title":"Cost-effectiveness of augmenting universal hepatitis B vaccination with immunoglobin treatment","volume":"131","author":"Chen","year":"2013","journal-title":"Pediatrics"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.4161\/hv.23827","article-title":"Economic analysis of the first 20 years of universal hepatitis B vaccination program in Italy: an a posteriori evaluation and forecast of future benefits","volume":"9","author":"Boccalini","year":"2013","journal-title":"Hum Vacc Immunother"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.vhri.2012.03.007","article-title":"Cost-effectiveness analysis of hepatitis B immunization in Vietnam: application of cost-effectiveness affordability curves in health care decision making","volume":"1","author":"Tu","year":"2012","journal-title":"Value Health Reg Iss"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1080\/21645515.2020.1845522","article-title":"Evaluating the cost-effectiveness of universal hepatitis B virus vaccination in Iran: a Markov model analysis","volume":"17","author":"Mokhtari","year":"2021","journal-title":"Hum Vacc Immunother"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S1473-3099(16)30204-3","article-title":"Requirements for global elimination of hepatitis B: a modelling study","volume":"16","author":"Nayagam","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1056\/NEJMoa1508660","article-title":"Tenofovir to prevent hepatitis B transmission in mothers with high viral load","volume":"374","author":"Pan","year":"2016","journal-title":"New Engl J Med"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1532604\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T05:25:39Z","timestamp":1744781139000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1532604\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":58,"alternative-id":["10.3389\/fpubh.2025.1532604"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2025.1532604","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"article-number":"1532604"}}